The Correlation of Magee Equationstm and Oncotype Dx® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response To Neoadjuvant Chemotherapy in Er+ and Her2- Breast Cancer

dc.contributor.author Soran,A.
dc.contributor.author Tane,K.
dc.contributor.author Sezgin,E.
dc.contributor.author Bhargava,R.
dc.coverage.doi 10.5152/ejbh.2020.5338
dc.coverage.doi 10.5152/ejbh.2020.5338
dc.date.accessioned 2020-07-18T08:34:03Z
dc.date.available 2020-07-18T08:34:03Z
dc.date.issued 2020
dc.description.abstract Objective: Oncotype DX® recurrence score (RS) can be predicted from Magee EquationsTM (MS) postoperatively. The aim of this study is to investigate correlation of MS with RS from pretreatment core needle biopsy (CNB) tissues, and their clinical usefulness in prediction of response to neoadjuvant chemotherapy (NCT) in estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer (BC). Materials and Methods: Pretreatment CNB tissue samples from 60 patients with ER+/HER2- invasive BC were analyzed for MS and RS correlation. MS and RS were categorized as follows: low (<18), intermediate (18–30), and high (≥ 31). Percentage Tumor size Reduction (%TR) was used to assess tumor response to NCT, and substantial %TR was defined as at least 50% reduction (≥50%TR). Correlation between MS and RS, and predictive factors for the ≥50%TR achievement were assessed. Results: MS and RS represented a strong correlation (Spearman's correlation; r=0.58, p<0.0001) as a continuous variable. As a categorical variable, the concordance between MS and RS was 43.3%, and it increased to 80% (r=0.61, p=0.003) with the exclusion of the intermediate risk categories. Although, there was pathologic complete response (pCR), MS showed the highest predictive power for the ≥50% TR achievement, none of the factors were statistically significant (p≥0.07). Conclusion: Our study demonstrated that there was a strong correlation between MS and RS from pretreatment biopsy tissue samples in ER+ and HER2- invasive BC. © 2020 by the Author(s). en_US
dc.description.sponsorship Genomic Health, (01-48) en_US
dc.identifier.doi 10.5152/ejbh.2020.5338 en_US
dc.identifier.doi 10.5152/ejbh.2020.5338
dc.identifier.issn 2587-0831
dc.identifier.scopus 2-s2.0-85098689954
dc.identifier.uri https://doi.org/10.5152/ejbh.2020.5338
dc.identifier.uri https://search.trdizin.gov.tr/en/yayin/detay/378611/the-correlation-of-magee-equationstm-and-oncotype-dxr-recurrence-score-from-core-needle-biopsy-tissues-in-predicting-response-to-neoadjuvant-chemotherapy-in-er-and-her2-breast-cancer
dc.identifier.uri https://hdl.handle.net/11147/8844
dc.language.iso en en_US
dc.publisher Galenos Publishing House en_US
dc.relation.ispartof European Journal of Breast Health en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Breast cancer en_US
dc.subject Magee Equations<sup>TM</sup> en_US
dc.subject neoadjuvant chemotherapy en_US
dc.subject Oncotype DX® recurrence score en_US
dc.subject pretreatment biopsy en_US
dc.title The Correlation of Magee Equationstm and Oncotype Dx® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response To Neoadjuvant Chemotherapy in Er+ and Her2- Breast Cancer en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.institutional Sezgin, Efe
gdc.author.scopusid 7003410848
gdc.author.scopusid 56358584800
gdc.author.scopusid 7003392648
gdc.author.scopusid 57203071202
gdc.bip.impulseclass C5
gdc.bip.influenceclass C5
gdc.bip.popularityclass C4
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department Izmir Institute of Technology en_US
gdc.description.departmenttemp Soran A., Division of Breast Surgery and Lymphedema Program, Magee-Womens Hospital of University of Pittsburgh Medical Center, Suite 2601, 300 Halket Street, Pittsburgh, PA, United States; Tane K., Division of Breast Surgery, Hyogo Cancer Center, Hyogo, Akashi, Japan, Division of Breast Surgery and Lymphedema Program, Magee-Womens Hospital of University of Pittsburgh Medical Center, Suite 2601, 300 Halket Street, Pittsburgh, PA, United States; Sezgin E., Department of Food Engineering, Laboratory of Nutrigenomics and Epidemiology, İzmir Institute of Technology, İzmir, Turkey; Bhargava R., Department of Pathology, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA, United States en_US
gdc.description.endpage 123 en_US
gdc.description.issue 2 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.startpage 117 en_US
gdc.description.volume 16 en_US
gdc.description.wosquality Q4
gdc.identifier.openalex W3015736635
gdc.identifier.pmid 32285033
gdc.identifier.trdizinid 378611
gdc.identifier.trdizinid 378611
gdc.identifier.wos WOS:000524026100008
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type TR-Dizin
gdc.oaire.accesstype GOLD
gdc.oaire.diamondjournal false
gdc.oaire.impulse 2.0
gdc.oaire.influence 2.9077944E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Pretreatment biopsy
gdc.oaire.keywords R
gdc.oaire.keywords Neoplasms. Tumors. Oncology. Including cancer and carcinogens
gdc.oaire.keywords Magee Equations (TM)
gdc.oaire.keywords Neoadjuvant chemotherapy
gdc.oaire.keywords magee equationstm
gdc.oaire.keywords pretreatment biopsy
gdc.oaire.keywords Breast cancer
gdc.oaire.keywords breast cancer
gdc.oaire.keywords Oncotype DX (R) recurrence score
gdc.oaire.keywords Medicine
gdc.oaire.keywords oncotype dx® recurrence score
gdc.oaire.keywords RC254-282
gdc.oaire.keywords neoadjuvant chemotherapy
gdc.oaire.popularity 4.5654485E-9
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 03 medical and health sciences
gdc.oaire.sciencefields 0302 clinical medicine
gdc.openalex.collaboration International
gdc.openalex.fwci 0.19209489
gdc.openalex.normalizedpercentile 0.42
gdc.opencitations.count 4
gdc.plumx.crossrefcites 3
gdc.plumx.mendeley 14
gdc.plumx.pubmedcites 2
gdc.plumx.scopuscites 6
gdc.scopus.citedcount 6
gdc.wos.citedcount 5
relation.isAuthorOfPublication.latestForDiscovery 77721b7d-10bb-4a8e-8cd8-10a1088bfb1b
relation.isOrgUnitOfPublication.latestForDiscovery 9af2b05f-28ac-4019-8abe-a4dfe192da5e

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Name:
ejbh-16-117-En.pdf
Size:
235.67 KB
Format:
Adobe Portable Document Format